No increase of immune response, including numbers of CD3+, CD4+ and CD8+ T cells, was detected in the non-tumour-bearing mice treated with P@aPDL1 and Vadimezan compared with those treated with PBS (Supplementary Fig. 12), which further indicates that the tumour specificity of the observed enhanced immune response in the metastatic breast tumour model. This evidence concerns the gene CD4 and neoplasm.